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Schematic	  view	  of	  SERM	  delivery	  to	  cancerous	  breast	  tissue	  following	  application	  of	  a	  topical	  formualtion	  
over	  a	  relatively	  large	  area	  of	  skin.	  
 2 
Abstract	  
The	   aim	   of	   this	   work	   was	   to	   evaluate	   the	   feasibility	   of	   delivering	   transdermally	   a	   series	   of	   highly	  
lipophilic	   compounds	   (log	   P	   ~4-­‐7),	   comprising	   several	   selective	   estrogen	   receptor	   modulators	   and	   a	  
modified	   testosterone	   (danazol).	   The	  maximum	   fluxes	  of	   the	  drugs	  were	  predicted	   theoretically	   using	  
the	  modified	  Potts	  &	  Guy	  algorithm	  (to	  determine	  the	  permeability	  coefficient	  (kp)	  from	  water)	  and	  the	  
calculated	   aqueous	   solubilities.	   The	   correction	   provided	   by	   Cleek	   &	   Bunge	   took	   into	   account	   the	  
contribution	   of	   the	   viable	   epidermal	   barrier	   to	   the	   skin	   permeation	   of	   highly	   lipophilic	   compounds.	  	  
Experimental	  measurements	  of	  drug	  fluxes	  from	  saturated	  hydroalcoholic	  solutions	  were	  determined	  in	  
vitro	   through	  excised	  pig	   skin.	  Overall,	   the	  predicted	   fluxes	  were	   in	  good	  general	  agreement	   (within	  a	  
factor	   of	   10)	   with	   the	   experimental	   results.	   	   Most	   of	   experimental	   fluxes	   were	   greater	   than	   those	  
predicted	   theoretically	   suggesting	   that	   the	  70:30	  v/v	  ethanol-­‐water	  vehicle	  employed	  may	  have	  had	  a	  
modest	   skin	   penetration	   enhancement	   effect.	   This	   investigation	   shows	   that	   the	   transdermal	   fluxes	   of	  
highly	   lipophilic	   compounds	   can	  be	   reasonably	  predicted	   from	   first	  principles	  provided	   that	   the	  viable	  
epidermis,	   underlying	   the	   stratum	   corneum,	   is	   included	   as	   a	   potentially	   important	   contributor	   to	   the	  
skin’s	   overall	   barrier	   function.	   	   Furthermore,	   the	   absolute	   values	   of	   the	   measured	   fluxes,	   when	  
considered	  in	  parallel	  with	  previous	  clinical	  studies,	  indicate	  that	  it	  might	  be	  feasible	  to	  topically	  deliver	  
a	  therapeutically	  useful	  amount	  of	  some	  of	  the	  compounds	  considered	  to	  cancerous	  breast	  tissue.	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1.	  Introduction	  
Selective	   estrogen	   receptor	   modulators	   (SERMs)	   are	   synthetic	   hormones	   that	   act	   as	   agonists	   or	  
antagonists	  of	  estradiol	  depending	  on	  the	  tissue.	  For	  example,	  SERMs	  are	  agonists	  in	  bone,	  liver,	  and	  the	  
cardiovascular	   system,	  antagonists	   in	  breast	   tissue,	  and	  mixed	  agonist/antagonists	   in	   the	  uterus	   [1,2].	  	  
Several	  SERMs	  are	  marketed	  or	  in	  clinical	  development,	  including	  tamoxifen,	  4-­‐hydroxytamoxifen	  (4-­‐OH	  
tamoxifen),	  toremifene,	  clomiphene,	  endoxifen	  and	  droloxifene	  [1-­‐3].	  Tamoxifen	  has	  been	  shown	  to	  be	  
the	  most	  important	  therapeutic	  agent	  for	  the	  treatment	  of	  estrogen	  receptor	  positive	  breast	  cancer	  for	  
the	  past	   three	  decades.	   It	   is	  widely	  used	   in	   adjuvant	  endocrine	   therapy	  of	   early	  breast	   cancer,	   in	   the	  
palliative	  treatment	  of	  advanced	  disease,	  and	  for	  prevention	  of	  breast	  cancer	  in	  high-­‐risk	  subjects	  [2,4].	  
It	  has	  also	  been	  evaluated	  in	  the	  treatment	  of	  mastalgia	  [5].	  In	  addition	  to	  its	  anti-­‐estrogenic	  activity	  in	  
the	  breast,	  tamoxifen	  also	  acts	  as	  an	  estrogen	  in	  the	  uterus	  [1,2].	  Thus,	  the	  most	  important	  side	  effects	  
of	   tamoxifen	   treatment	   are	   development	   of	   endometrial	   polyps,	   endometriosis	   and	   increased	   risk	   of	  
endometrial	   cancer	   [6].	   Tamoxifen	   also	   has	   other	   dose	   dependent	   side	   effects	   including	   hot	   flushes,	  
deep	  vein	  thrombosis,	  retinopathy,	  cataract,	  and	  corneal	  opacities	  [3,7].	  	  
Tamoxifen	   is	   extensively	   biotransformed	   to	   metabolites	   that	   have	   different	   potencies	   and	   anti-­‐
estrogenic	  activities	  [8-­‐10].	  High	  inter-­‐individual	  variability	  in	  tamoxifen	  response	  has	  been	  attributed	  to	  
the	  different	  degrees	  of	  metabolism	  [10].	  Tamoxifen	  has	  anti-­‐estrogenic	  activity	  but	  it	  is	  also	  a	  pro-­‐drug.	  
Its	  efficacy	  also	  depends	  on	  its	  major	  metabolites,	  4-­‐hydroxy-­‐tamoxifen	  (4–OH	  tamoxifen,	  afimoxifene)	  
and	   N-­‐desmethyl-­‐4-­‐hydroxytamoxifen	   (endoxifen).	   The	   binding	   affinities	   of	   4-­‐OH	   tamoxifen	   and	  
endoxifen	  are	  both	  25	  times	  greater	  for	  ERα	  and	  56	  times	  greater	  for	  ERβ	  than	  that	  of	  tamoxifen	  [9,10].	  
4–OH	   tamoxifen	   (afimoxifene),	   the	   most	   active	   metabolite	   of	   tamoxifen	   has	   higher	   anti-­‐estrogenic	  
potency	  than	  the	  parent	  drug	  [11].	  Endoxifen,	  another	  major	  metabolite	  of	  tamoxifen	  (N-­‐desmethyl-­‐4-­‐
hydroxytamoxifen),	   is	   found	   in	   higher	   concentration	   than	   that	   of	   4-­‐OH	   tamoxifen	   [9,10].	   Although	   its	  
pharmacological	  activity	  has	  not	  been	  explained	  in	  detail,	  the	  potency	  of	  endoxifen	  has	  been	  shown	  to	  
be	  similar	  to	  4-­‐OH	  tamoxifen	  in	  terms	  of	  both	  estrogen	  binding	  and	  inhibition	  of	  estradiol-­‐induced	  cell	  
proliferation	  [9,10].	   In	  recent	  years,	   it	  has	  been	  shown	  to	  be	  a	  new	  potent	  anti-­‐estrogen	  agent	  for	  the	  
treatment	  of	  breast	  cancer	  [12-­‐14].	  The	  clinical	  trial	  studies	  have	  been	  carried	  out	  on	  oral	  administration	  
of	  endoxifen	  hydrochloride	  [15,16].	  
Danazol	  has	  also	  been	  evaluated	  for	  the	  treatment	  of	  pain	  and	  nodularity	  related	  to	  cyclical	  mastalgia.	  
Although	  significant	  decrease	   in	  pain	  and	  nodularity	  was	  observed	  compared	   to	  placebo,	  oral	  danazol	  
treatment	  caused	  significant	  side	  effects	  that	  restrict	  its	  use	  for	  long-­‐term	  treatment	  [17].	  	  
To	  circumvent	  the	  variability	  and	  patient	  compliance	  problems	  (including	  adverse	  effects)	  of	  oral	  SERMs,	  
their	  direct	  transdermal	  administration	  to	  breast	   for	  example,	  to	  treat	  benign	  diseases,	  and	  mastalgia,	  
and	   for	  prophylactic	  protection	  of	  healthy,	  but	  at	   risk	  women	  has	  been	  proposed	  and	  considered.	  For	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example,	  the	  skin	  penetration	  of	  tamoxifen	  in	  vitro	  in	  the	  presence	  of	  different	  chemical	  enhancers	  [18-­‐
21]	   has	   been	   assessed,	   as	   has	   the	   liposomal	   delivery	   of	   the	   drug	   [22-­‐24].	   Clinically,	   the	   transdermal	  
delivery	  of	  4-­‐OH	   tamoxifen	  has	  been	  evaluated	   [25-­‐28],	  and	  promising	   results	  have	  been	  obtained.	   In	  
post-­‐menopausal	  women	  with	  estrogen	  receptor	  positive	  breast	  cancer,	  direct	  topical	  application	  to	  the	  
breast	   of	   4-­‐OH	   tamoxifen	   gel	   resulted	   in	   anti-­‐estrogenic	   activity	   in	   the	   tissue,	   and	   systemic	  
concentrations	   of	   the	   drug	   that	   were	  much	   less	   than	   those	  measured	   after	   oral	   administration	   [27].	  
Topical	  delivery	  was	  shown	  to	  inhibit	  tumour	  proliferation	  equivalent	  to	  that	  achieved	  with	  an	  oral	  dose	  
of	  20	  mg/day.	  In	  a	  phase	  II	  clinical	  trial	  of	  4-­‐OH	  tamoxifen,	  the	  efficacy	  of	  a	  topical	  gel	  in	  the	  treatment	  
of	   cyclical	   mastalgia	   was	   demonstrated	   with	   high	   tolerability	   and	   safety	   [28].	   This	   gel	   has	   also	   been	  
investigated	   in	  another	  phase	   II	   trial	   for	   the	   treatment	  of	  women	  with	  newly	  diagnosed	  ductal	  breast	  
carcinoma	  in	  situ	  [29].	  Furthermore,	  given	  the	  potential	  of	  oral	  endoxifen	  to	  treat	  breast	  cancer	  [12-­‐14],	  
the	  transdermal	  delivery	  of	   this	   tamoxifen	  metabolite	  has	  been	  assessed	  [30,31];	   the	  skin	  penetration	  
enhancer,	  oleic	  acid,	  increased	  drug	  delivery	  sufficiently	  that	  this	  approach	  may	  be	  feasible	  for	  the	  direct	  
input	  of	  the	  SERM	  to	  breast	  tissue.	  
However,	  the	  skin	  is	  a	  complex	  membrane	  the	  outermost	  layer	  of	  which,	  the	  stratum	  corneum	  (SC),	  has	  
been	  bioengineered	  to	  be	  a	  very	  efficient	  barrier	  to	  the	  ingress	  of	  xenobiotics,	  including	  drugs.	  Indeed,	  
skin	   penetration	   is	   very	   sensitive	   to	   the	   physicochemical	   properties	   of	   the	   permeant,	   and	   is	   most	  
favourable	  for	  low	  molecular	  weight	  compounds	  (<	  500	  Daltons	  being	  most	  typically	  cited)	  and	  those	  of	  
moderate	   lipophilicity	   (log	   (octanol-­‐water	   partition	   coefficient),	   log	   P	   ~	   1-­‐3)	   [32].	   SERMs,	   though,	   are	  
typically	  more	   lipophilic	  with	   log	  P	  values	  of	  5	  or	  more,	  suggesting	  that	  their	  uptake	   into	  the	  skin	  may	  
well	  be	  controlled	  by	  the	  rate	  at	  which	  they	  are	  able	  to	  transfer	  out	  of	  the	  SC	  and	  into	  the	  underlying,	  
much	  more	   aqueous,	   viable	   layers	  of	   the	   skin.	   These	   factors	  have	  been	   successfully	  modelled	   [33,34]	  
such	  that	  a	  drug’s	  skin	  permeability,	  and	  its	  maximum	  flux	  through	  the	  barrier,	  may	  be	  predicted	  from	  a	  
simple	  set	  of	  algorithms	  [35].	  
In	  this	  paper,	  therefore,	  this	  theoretical	  approach	  has	  been	  used	  to	  estimate	  the	  transdermal	  fluxes	  of	  a	  
series	   of	   highly	   lipophilic	   SERMs,	   as	   well	   as	   that	   of	   danazol,	   and	   to	   compare	   these	   results	   with	  
experimental	  measurements	  made	  in	  vitro	  across	  porcine	  skin	  (a	  widely	  accepted	  model	  for	  the	  human	  
counterpart	   [36]).	   Finally,	   the	   data	   obtained	   are	   considered	   in	   light	   of	   the	   anticipated	   drug	   levels	  
required	   for	   local	   efficacy	   in	   breast	   tissue	   with	   a	   view	   to	   evaluating	   the	   potential	   feasibility	   and	  
optimisation	  of	  a	  topical	  delivery	  formulation.	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2.	  Materials	  and	  Methods	  
2.1.	  Chemicals	  and	  reagents	  
Tamoxifen	   citrate,	   clomiphene	   citrate,	   and	   cetrimide	   were	   purchased	   from	   Sigma	   (Poole,	   UK).	  
Droloxifene	   citrate	   and	   endoxifen,	   4-­‐OH	   tamoxifen	   were	   supplied	   by	   Besins	   Healthcare	   SA,	   Brussels,	  
Belgium.	  Toremifene	  and	  danazol	  were	  obtained	  from	  Axxora	  (Nottingham,	  UK).	  HPLC	  grade	  acetonitrile	  
and	   methanol,	   absolute	   ethanol,	   triethanolamine	   and	   trifluoroacetic	   were	   from	   Fischer	   Scientific	  
(Loughborough,	  UK).	  
2.2.	  Calculation	  of	  lipophilicity	  and	  aqueous	  solubility	  of	  SERMs	  
Log	   (octanol-­‐water	  partition	  coefficient)	   (log	  P)	  values	  and	  aqueous	  solubilities	   (Cw,sat)	  were	  estimated	  
for	   the	  unionised	   forms	  of	   the	  drugs	  using	   the	  ALOGPS	  2.1	   algorithm	   from	   the	  Virtual	  Computational	  
Chemistry	   Laboratory	   (http://www.vcclab.org),	   and	   from	   ChemSpider	   (http://www.chemspider.com).	  
The	  former	  provided	  8	  calculated	  values	  of	  log	  P	  and	  2	  for	  Cw,sat;	  the	  latter	  furnished	  one	  log	  P	  estimate	  
(which	  was	  identical	  to	  one	  of	  the	  8	  from	  the	  VCCL)	  and	  2	  additional	  estimates	  of	  Cw,sat,	  one	  based	  on	  
the	  calculated	  log	  P,	  the	  other	  from	  a	  molecular	  fragment	  approach.	  The	  mean	  and	  standard	  deviation	  
of	  the	  log	  P	  (n=8)	  and	  Cw,sat	  (n=4)	  values	  were	  subsequently	  determined.	  	  	  	  
2.3.	  Predictive	  model	  of	  drug	  flux	  across	  skin	  
The	  steady-­‐state	  diffusion	  of	  a	  drug	  across	  skin	  may	  be	  described	  by	  Fick’s	  first	  law:	  	  
	   Jmax	  =	  (D/h)KSC/vCv,sat	  =	  kpCv,sat	  	  	   	   	   	   	   	   (Eq.	  1)	  
where	  Jmax	  is	  the	  maximum	  drug	  flux	  (amount	  per	  unit	  area	  per	  unit	  time);	  D	  is	  its	  diffusion	  coefficient	  in	  
the	  stratum	  corneum	  (SC);	  KSC/v	   is	  the	  drug’s	  SC-­‐vehicle	  partition	  coefficient,	  h	   is	  the	  path	  length	  taken	  
by	   the	   penetrant	   through	   the	   SC,	   and	   Cv,sat	   is	   saturated	   solubility	   of	   the	   drug	   in	   the	   vehicle.	   The	  
permeability	  coefficient	  of	   the	  drug	  through	  the	  SC	  (kp)	   following	   its	  application	   in	  an	  aqueous	  vehicle	  
may	  be	  predicted	  from	  Eq.	  2	  [33]:	  	  
log	  kp	  	  (cm/h)	  =	  	  -­‐	  2.7(±0.8)	  +	  0.71(±0.06)log	  P	  	  –	  	  0.0061(±0.0006)MW	  	  	  	  	  	  	  	  	   (Eq.	  2)	  
where	  P	  is	  the	  compound’s	  octanol-­‐water	  partition	  coefficient	  and	  MW	  is	  its	  molecular	  weight.	  For	  very	  
lipophilic	  compounds,	  the	  contribution	  of	  the	  viable	  skin	  layers	  to	  the	  skin’s	  barrier	  must	  be	  taken	  into	  
account	  through	  a	  correction	  to	  the	  permeability	  coefficient	  proposed	  by	  Cleek	  and	  Bunge	  [34]:	  
kp,corr	  =	  kp/{1	  +	  (kpMW½/2.6)}	   	   	   	   	   	   (Eq.	  3)	  
It	  follows,	  therefore,	  that	  an	  estimate	  of	  Jmax	  can	  be	  obtained	  via	  Eq.	  1	  by	  multiplying	  the	  value	  of	  kp,corr	  
(Eq.	  3)	  by	  the	  aqueous	  solubility	  of	  the	  drug.	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It	   should	  be	  pointed	  out	   that	   the	  derivation	  of	  Eq.	  3	  assumed	  a	  nominal	  viable	   tissue	   thickness	  of	  0.1	  
mm;	  i.e.,	  a	  value	  approximately	  equivalent	  to	  the	  thickness	  of	  the	  epidermis,	  rather	  than	  that	  of	  a	  skin	  
sample	  typically	  used	  in	  an	  in	  vitro	  Franz	  cell	  experiment	  –	  see	  below.	  	  While	  this	  might	  be	  expected	  to	  
undermine	   a	   comparison	   of	   experimental	   and	   theoretically	   predicted	   flux,	   for	   the	   very	   lipophilic	  
compounds	  considered	  here,	  the	  rate-­‐determining	  step	  in	  their	  penetration	  is	  effectively	  mass	  transfer	  
at	  the	  stratum	  corneum-­‐viable	  tissue	  interface;	  subsequent	  diffusion	  through	  the	  viable	  tissue	  is	  likely	  to	  
be	  relatively	  fast	  and	  the	  impact	  of	  the	  absolute	  thickness	  of	  this	  layer	  will	  be	  modest	  at	  most.	  
2.4.	  Solubility	  determination	  
The	   saturated	   solubilities	   of	   danazol	   and	   the	   six	   SERMs	   considered	   were	   determined	   in	   a	   series	   of	  
ethanol-­‐water	  mixtures	  (40:60,	  50:50,	  60:40	  and	  70:30,	  v/v)	  and	  in	  the	  aqueous	  cetrimide	  solution	  (3%,	  
w/v)	  used	  as	  the	  receptor	  fluid	  in	  the	  skin	  permeation	  experiments.	  	  An	  excess	  of	  each	  compound	  was	  
added	   to	   1	   mL	   of	   the	   solvent	   and	   the	   suspensions	   were	   shaken	   for	   at	   least	   24	   hours	   at	   room	  
temperature	  to	  ensure	  saturation.	  The	  samples	  then	  were	  filtered	  through	  a	  0.45	  µm	  membrane	  filter	  
(Millex®	  Syringe	  Filter,	  Milipore),	  and	  saturated	  concentrations	  were	  determined	  by	  HPLC	  analysis	  after	  
appropriate	  dilution	  (see	  below).	  
2.5.	  Skin	  permeation	  experiments	  
Porcine	  abdominal	  skin	  was	  obtained	  from	  a	  local	  slaughterhouse	  and	  cleaned	  with	  cold	  water.	  The	  fat	  
and	  subcutaneous	   layers	  were	  separated	  carefully	  with	  a	  scalpel.	  The	  tissue	  was	  then	  dermatomed	  to	  
~750	  µm	  thickness	  (ZimmerTM,	  Dover,	  OH)	  and	  cut	  into	  small	  pieces,	  which	  were	  wrapped	  individually	  in	  
ParafilmTM	  and	  stored	  at	  -­‐20°C	  until	  required.	  Five	  to	  ten	  replicates	  were	  performed	  for	  each	  compound	  
using	  skin	  from	  at	  least	  two	  different	  animals.	  
The	   permeation	   studies	   were	   carried	   out	   using	   opaque	   side-­‐by-­‐side	   diffusion	   cells	   with	   an	   effective	  
diffusion	  area	  of	  0.71	  cm2.	  The	  receptor	  compartment	  had	  a	  volume	  of	  3.2	  ml	  and	  was	  maintained	  at	  37	  
(±0.5)°C	  by	  circulating	  warmed	  water	  through	  a	   jacket	  surrounding	  the	  cell.	  The	  receptor	  solution	  was	  
3%	   w/v	   cetrimide	   and	   ensured	   that	   sink	   conditions	   [21]	   were	   maintained.	   The	   receptor	   was	   stirred	  
continuously	  with	   a	   Teflon-­‐coated	  magnetic	   bar	   at	   100	   rpm.	   The	   skin	  was	   allowed	   to	   defrost	   and	   re-­‐
hydrate	  in	  isotonic	  saline	  solution	  for	  1	  h	  before	  the	  permeation	  experiment	  began.	  3	  ml	  of	  a	  saturated	  
solution	  of	  each	  compound	  in	  70:30	  v/v	  ethanol-­‐water	  was	  introduced	  into	  the	  donor	  chamber	  ensuring	  
maximum	  thermodynamic	  activity.	  Experiments	  were	  performed	  under	  complete	  occlusion.	  	  At	  1,	  9,	  20	  
and	  24	  hours	  post-­‐application,	  1	  ml	  samples	  were	  taken	  from	  the	  receiver	  compartment	  and	  replaced	  
with	  the	  same	  volume	  of	  fresh,	  temperature-­‐equilibrated	  receptor	  fluid.	  Samples	  were	  filtered	  through	  
a	  0.45	  μm	  membrane	   filter,	  and	  the	  amount	  of	  penetrant	  was	  determined	  by	  HPLC	  using	   the	  method	  
described	  below.	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2.6.	  Analytical	  method	  
Drug	  concentrations	  were	  determined	  by	  HPLC	  (Jasco	  model	  PU-­‐2080	  Plus	  pump;	  model	  AS-­‐2051	  plus	  
auto-­‐sampler;	   UV	   detector	   (Jasco,	   Japan,	  Model	   UV-­‐2975	   Plus)).	   Chromatographic	   resolution	   of	   4-­‐OH	  
tamoxifen,	   tamoxifen	   citrate,	   clomifene	   citrate,	   endoxifen,	   droloxifene	   citrate	   and	   toremifene	   was	  
achieved	  on	  a	  C18	  reverse-­‐phase	  column	  (5	  µm,	  250	  mm	  x	  4.6	  mm,	  HiQ	  sil,	  KYA	  Tec,	  Japan)	  with	  a	  guard	  
column	  (ODS	  Hypersil	  5	  μm,	  10	  mm	  x	  4	  mm,	  Thermo	  Electron	  Corporation,	  UK).	  Separation	  of	  danazol	  
used	  a	  C18	   reverse-­‐phase	   column	   (5	  µm,	  150	  mm	  x	  4.6	  mm,	  Acclaim)	  with	   the	   same	  guard	   column	  as	  
above.	   The	   analysis	   details	   for	   each	   compound	   are	   summarized	   in	   Table	   1.	   The	  mobile	   phases	   were	  
filtered	   through	   a	   0.45	   μm	   membrane.	   The	   injection	   volume	   was	   50	   μL.	   Calibrations	   employed	   the	  
external	   standard	  method,	   and	   standard	   solutions	   were	   prepared	   in	  methanol.	   Dilutions	   were	  made	  
with	  3%	  w/v	  cetrimide	  solution.	  The	  calibration	  curve	  was	  established	  between	  0.25	  and	  50	  μg.mL-­‐1	  for	  
4-­‐OH	  tamoxifen,	  and	  in	  the	  range	  0.1	  -­‐	  20	  μg.mL-­‐1	  for	  all	  other	  compounds	  (r2	  >	  0.999).	  Each	  sample	  was	  
assayed	  in	  triplicate,	  and	  all	  HPLC	  methods	  were	  fully	  validated.	  	  Accuracy,	  expressed	  as	  a	  percentage	  of	  
the	  mean	   recovery,	   ranged	   from	   98%	   to	   104%;	   precision,	   expressed	   as	   a	   relative	   standard	   deviation	  
(RSD),	  was	  less	  than	  2%.	  
	  
Table	  1.	  Chromatographic	  conditions	  for	  HPLC	  analysis.	  
a	  TFA:	  Trifluoroacetic	  acid	  
b	  TEA:	  Triethanolamine	  
	  
Compound	   Mobile	  phase	   Flow	  rate	  (ml.min-­‐1)	   UV	  (nm)	  
Clomiphene	  citrate	   Methanol:	  water:	  TFAa	  	  (75:	  25:0.1)	   0.6	   235	  
Danazol	   Acetonitrile	  :	  water	  (65:35)	   1.0	   287	  
Droloxifen	  citrate	  
Methanol	  :	  acetonitrile:	  water:	  acetic	  acid	  :	  TEAb	  	  
(350	  :	  350	  :	  300	  :	  2	  :	  1)	  
1.0	   235	  
Endoxifen	  
Methanol	  :	  acetonitrile:	  water:	  acetic	  acid:	  TEAb	  	  
(350	  :	  350	  :	  300	  :	  2	  :	  1)	  
0.7	   244	  
4-­‐OH	  Tamoxifen	  
Methanol	  :	  acetonitrile	  :	  water	  :	  acetic	  acid:	  TEAb	  	  
(350	  :	  350	  :	  300:	  2:	  1)	  
1.0	   243	  
Tamoxifen	  citrate	   Methanol	  :	  water	  :	  TFAa	  (75	  :	  25	  :	  0.1)	   0.6	   237	  
Toremifene	  
Methanol	  :	  acetonitrile	  :	  water	  :	  TFAa	  	  
(500	  :	  310	  :	  190	  :	  0.35)	  
0.5	   237	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3.	  Results	  &	  Discussion	  
The	   first	   step	   in	   the	   research	   described	   here	   was	   to	   predict	   the	   maximum	   skin	   fluxes	   (Jmax)	   of	   the	  
lipophilic	   drugs	   considered.	   To	   do	   so,	   as	   explained	   above,	   required	   knowledge	   of	   MW,	   log	   P	   and	  
aqueous	  solubility	   (Cw,sat).	  The	   former	  were	  easily	   looked	  up,	  while	  estimation	  of	   log	  P	  and	  Cw,sat	  were	  
calculated	  for	  the	  unionised	  forms	  of	  the	  drugs	  using	  freely	  accessible	  algorithms.	  The	  results	  obtained	  
are	  in	  Table	  2.	  There	  were	  8	  separate	  calculations	  of	   log	  P	  and	  4	  of	  Cw,sat;	  while	  the	  former	  were	  quite	  
consistent	  with	  a	  coefficient	  of	  variation	  between	  10	  and	  15%	  of	  the	  mean,	  the	  latter	  differed	  far	  more	  
and,	   for	   all	   drugs	   except	   danazol,	   one	   of	   the	   estimates	   was	   a	   clear	   statistical	   outlier	   (at	   p<0.05,	  
www.graphpad.com/quickcalcs/Grabsbs1.cfm).	   This	   value	   was	   not	   used,	   therefore,	   to	   determine	   the	  
average	  Cw,sat	  required	  for	  the	  calculation	  of	  Jmax.	  
	  
Table	  2.	   Estimated	  log	  P	  (n	  =	  8)	  and	  Cw,sat	   (n	  =	  3,	  except	  for	  danazol	  for	  which	  n	  =	  4)	  values	  (mean	  ±	  
standard	  deviation)	  for	  the	  compounds	  studied.	  
Compound	   MW	  (Da)	   log	  P	   Cw,sat	  (μg/mL)	  
Clomiphene	   405.97	   6.65	  ±	  0.76	   0.16	  ±	  0.23	  
Danazol	   337.46	   4.14	  ±	  0.57	   10.3	  ±	  8.29	  
Droloxifene	   387.52	   5.95	  ±	  0.84	   1.77	  ±	  1.20	  
Endoxifen	   373.50	   5.45	  ±	  0.64	   1.97	  ±	  0.96	  
4-­‐OH	  Tamoxifen	   387.52	   5.96	  ±	  0.85	   1.77	  ±	  1.20	  
Tamoxifen	   371.52	   6.39	  ±	  0.84	   0.41	  ±	  0.53	  
Toremifene	   405.97	   6.06	  ±	  0.75	   0.38	  ±	  0.36	  
	  
The	  corrected	  skin	  permeability	  coefficients	  (determined	  from	  Eqs.	  2	  and	  3)	  [33,34],	  and	  the	  calculated	  
Jmax	  values	   for	  seven	  drugs	  are	   in	  Table	  3.	  The	  final	  estimates	  of	   the	  permeability	  coefficients	  of	   these	  
very	  lipophilic	  compounds	  are	  in	  the	  range	  of	  0.01	  to	  0.1	  cm.hr-­‐1,	  consistent	  with	  the	  rate-­‐limiting	  role	  of	  
the	   viable,	   aqueous	   skin	   tissue	   in	   their	   percutaneous	   transport	   [37].	   Nevertheless,	   the	   predicted	   Jmax	  
values	  are	  no	  more	  than	  150	  ng.cm-­‐2.hr-­‐1,	  reflecting	  the	  very	  low	  aqueous	  solubilities	  of	  these	  drugs.	  It	  
should	   be	   emphasized	   that	   all	   calculations	   are	   based	   on	   the	   properties	   of	   the	   unionised	   compounds,	  










Clomiphene	   0.097	   0.015	  
Danazol	   0.015	   0.15	  
Droloxifene	   0.072	   0.13	  
Endoxifen	   0.052	   0.10	  
4-­‐OH	  Tamoxifen	   0.073	   0.13	  
Tamoxifen	   0.101	   0.042	  
Toremifene	   0.069	   0.026	  
	  
Figure	  1.	   Solubility	   of	   the	   compounds	   studied	   in	   different	   mixtures	   of	   ethanol	   (the	   %v/v	   of	   which	   is	  
indicated	   on	   the	   graph)	   and	   water.	   Each	   value	   shown	   represents	   the	   mean	   of	   3	   replicates	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The	   second	   component	   of	   the	  work	  was	   to	  measure	   Jmax	   for	   the	   SERMs	   and	   danazol	   experimentally.	  
Because	   of	   the	   extremely	   poor	   water	   solubilities	   of	   these	   compounds,	   their	   delivery	   from	   saturated	  
ethanol-­‐water	   mixtures	   was	   selected	   so	   that	   drug	   transport	   would	   not	   be	   affected	   by	   significant	  
depletion	  of	  the	  active	  moiety	  in	  the	  vehicle.	  Of	  course,	  according	  to	  Eq.	  1,	  Jmax	  should	  not	  be	  affected	  by	  
the	   nature	   of	   the	   vehicle	   when	   the	   drug	   is	   applied	   as	   a	   saturated	   solution	   (i.e.,	   at	   its	   maximum	  
thermodynamic	  activity),	  provided	  that	  the	  vehicle	  itself	  does	  not	  alter	  skin	  barrier	  function	  in	  some	  way	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[33].	  The	  measured	  solubilities	  of	  the	  drug	  in	  various	  ethanol-­‐water	  mixtures	  are	  in	  Figure	  1	  and	  these	  
results	   informed	  the	  choice	  of	  70:30	  v/v	  ethanol-­‐water	  vehicle	  for	  the	  skin	  penetration	  studies:	  at	  this	  
co-­‐solvent	  ratio,	  it	  was	  considered	  that	  all	  the	  compounds	  under	  study	  had	  sufficient	  solubility	  to	  ensure	  
that	  quantification	  of	  their	  absorption	  would	  be	  unambiguously	  measurable.	  
The	  cumulative	  amounts	  of	  the	  7	  drugs	  absorbed	  across	  the	  skin	  in	  24	  hours	  are	  in	  Table	  4.	  Because	  of	  
the	  low	  fluxes	  observed,	  it	  was	  not	  possible	  to	  sample	  the	  receptor	  solution	  with	  sufficient	  frequency	  to	  
obtain	   a	   complete	   permeation	   profile	   or	   to	   determine	   a	   classic	   lag-­‐time.	   	   In	   any	   case,	   for	   the	   drug	  
delivery	  application	  envisaged,	  the	  treatment	  would	  obviously	  be	  chronic	  and	  would	  involve	  repetitive	  
administration	  to	  the	  same	  area(s)	  of	  skin.	   	  Presumably,	  this	  would	  ultimately	  permit	  establishment	  of	  
something	  close	  to	  steady-­‐state	  conditions	  and	  the	  duration	  of	  the	   initial	   lag	  time	  becomes	   irrelevant.	  	  	  
An	   approximation	   to	   the	   experimental	   Jmax	  was	   therefore	   derived	   by	   dividing	   the	   cumulative	   delivery	  
during	   a	   1-­‐day	   exposure	   by	   24	   hours	   -­‐	   these	   values	   are	   also	   in	   Table	   4.	   Comparison	  of	   the	   predicted	  
maximum	  fluxes	  in	  Table	  3	  with	  those	  in	  Table	  4	  is	  illustrated	  in	  Figure	  2.	  	  While	  all	  the	  ratios	  are	  within	  
an	  order	  of	  magnitude	  of	  the	  ideal	  value	  of	  1	  (in	  other	  words,	  in	  perfectly	  acceptable	  agreement	  given	  
the	   error	   associated	  with	   the	   prediction	   –	   see	   Eqn	   2),	  most	   of	   experimental	   fluxes	  were	   higher	   than	  
those	   predicted	   theoretically.	   	   This	  may	   indicate	   that	   the	   use	   of	   the	   70:30	   v/v	   ethanol-­‐water	   vehicle	  
under	  occlusion	  had	  a	  modest	  skin	  penetration	  enhancement	  effect.	  
	  
Table	  4.	   Cumulative	  transdermal	  delivery	  in	  24	  hours	  (Q24)	  and	  estimated,	  experimental	  skin	  flux	  (Jexpt	  






Area	  (cm2)	  required	  to	  
deliver	  1	  mg	  in	  24	  hrsa	  
Clomiphene	  	  citrate	   2.4	  ±	  2.3	   0.10	  ±	  0.09	   417	  	  [2749]	  
Danazol	   7.2	  ±	  9.1	   0.30	  ±	  0.08	   139	  	  [28]	  
Droloxifene	  citrate	   1.3	  ±	  0.8	   0.06	  ±	  0.03	   694	  	  [326]	  
Endoxifen	   23	  ±	  12	   0.94	  ±	  0.50	   44	  	  	  	  [407]	  
4-­‐OH	  Tamoxifen	   13	  ±	  6.3	   0.52	  ±	  0.30	   80	  	  	  	  [324]	  
Tamoxifen	  citrate	   3.3	  ±	  1.9	   0.14	  ±	  0.08	   297	  	  [995]	  
Toremifene	   5.1	  ±	  3.5	   0.21	  ±	  0.10	   198	  	  [1604]	  
aThe	   first	   value	   is	   determined	   from	   the	   experimental	   skin	   permeation	   data	   (i.e.,	   area	   =	  
1000/Q24);	  the	  second	  number	  (in	  square	  parentheses)	   is	  calculated	  from	  the	  theoretically	  
predicted	  fluxes	  in	  Table	  3	  (i.e.,	  area	  =	  1000/(Jmax	  x	  24)).	  
From	   the	  predicted	   and	   experimental	   fluxes,	   it	   is	   possible	   to	   evaluate	   the	   skin	   area	   across	  which	   Jmax	  
would	  have	   to	  be	   sustained	   to	  deliver	   1	  mg	  of	   drug	  over	   a	   24	  hours	   period.	   These	   values	   are	   also	   in	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Table	  4	  and	  suggest	  that	  the	  conventional	  transdermal	  delivery	  approach	  for	  the	  SERMs	  (whereby	  the	  
effective	  plasma	  levels	  of	  a	  drug	  following	  either	  oral	  or	  sublingual	  or	  intravenous	  delivery	  are	  matched	  
by	  those	  achieved	  post-­‐application	  of	  a	  patch)	  is	  simply	  not	  feasible	  as	  typical	  daily	  doses	  of	  the	  SERMs	  































Figure	  2.	   Ratios	  of	  experimental	  to	  theoretical	  fluxes	  of	  the	  compounds	  studied.	  
On	  the	  other	  hand,	  instead	  of	  addressing	  the	  drug	  delivery	  challenge	  to	  cancerous	  breast	  tissue	  from	  the	  
“inside-­‐out”	  (i.e.,	  deliver	  the	  drug	  to	  the	  central	  compartment	  and	  wait	  for	  it	  to	  distribute	  to	  peripheral	  
tissues),	  consider	  topical	  administration	  from	  the	  “outside-­‐in”	  to	  achieve	  the	  target	  site	  levels	  required	  
via	   transport	   through	   the	   skin,	   but	   with	   significantly	   reduced	   systemic	   exposure.	   If	   one	   assumes	   the	  
application	  of	  a	  formulation	  that	  can	  sustain	  Jmax	  over	  the	  dosing	  period	  when	  administered	  to	  the	  entire	  
surface	  of	   an	   “average”	  breast	   (surface	  area	  ~200	   cm2,	  mass	  ~750	  g)	   [38],	   then	   the	   resulting	  delivery	  
rates,	   in	   nanograms	   of	   drug	   per	   gram	   of	   tissue	   per	   hour,	   based	   on	   predicted	   and	   experimental	   Jmax	  
determinations	   are	   reported	   in	   Table	   5.	   These	   tissue	   delivery	   rates	   cannot	   be	   readily	   converted	   into	  
steady-­‐state	   concentrations	   because	   the	   local	   clearance	   of	   drug	   from	   breast	   tissue	   (or,	   indeed,	   from	  
different	  compartments	  within	  breast	   tissue)	   is	  not	  known.	  While	   it	  may	  ultimately	  be	  possible	  to	  use	  
the	  increasingly	  sophisticated	  models	  being	  developed	  to	  characterise	  skin	  clearance	  [39	  and	  references	  
therein],	   the	   calculated	   delivery	   rates	   can	   be	   compared	   for	   now	   with	   tissue	   levels	   that	   have	   been	  
measured	  and	  reported	  in	  other	  studies.	  	  	  
For	  example,	  tamoxifen	  and	  its	  metabolite	  concentrations	  have	  been	  measured	  in	  serum,	  normal	  breast	  
tissue	  and	  in	  breast	  tumour	  after	  repeated	  daily	  oral	  doses	  of	  1,	  5	  and	  20	  mg	  [8].	  	  The	  resulting	  serum	  
and	  breast	   tumour	   levels	  of	   tamoxifen	  were	  7.5,	  25.2	  and	  83.6	  ng.mL-­‐1,	   and	  78.2,	  272	  and	  744	  ng.g-­‐1,	  
respectively.	  	  Given	  the	  range	  of	  tissue	  delivery	  rates	  calculated	  in	  Table	  5	  for	  this	  drug,	  it	  would	  appear	  
plausible	  that	  its	  topical	  application	  to	  the	  breast	  in	  a	  suitable	  formulation	  may,	  at	  steady-­‐state,	  sustain	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tissue	   concentrations	  within	   the	   range	  achieved	  by	  oral	   administration.	   	   In	   the	   same	   study,	   the	   same	  
compartments	   were	   also	   analysed	   for	   4-­‐OH	   tamoxifen,	   which	   is	   ~25-­‐50	   times	  more	   potent	   than	   the	  
parent	  drug	  due	  to	  its	  higher	  affinity	  for	  estrogen	  receptors	  [11].	  	  Following	  the	  oral	  administration	  of	  1,	  
5	  and	  20	  mg	  of	  tamoxifen,	  the	  serum	  and	  breast	  cancer	  tissue	  levels	  of	  the	  4-­‐OH	  metabolite	  were	  0.6,	  
1.3	  and	  3.1	  ng.mL-­‐1,	  and	  0.4,	  4.4	  and	  28.5	  ng.g-­‐1,	  respectively	  [8].	  
	  
Table	  5.	   Calculated	  delivery	  rates	  of	  the	  compounds	  studied	  into	  breast	  tissue	  when	  applied	  topically	  
in	  a	  vehicle	  capable	  of	   sustaining	  drug	  delivery	  at,	  or	   close	   to,	   the	  maximum	  percutaneous	  
flux	  possible	  (estimates	  based	  upon	  an	  application	  area	  of	  200	  cm2	  over	  a	  tissue	  mass	  of	  750	  
g).	  
Compound	  
Calculated	  delivery	  rate	  based	  on	  
experimentally	  measured	  flux	  
(ng.hr-­‐1	  per	  gram	  of	  tissue)	  
Calculated	  delivery	  rate	  based	  
on	  maximum	  theoretical	  flux	  
(ng.hr-­‐1	  per	  gram	  of	  tissue)	  
Clomiphene	  	  citrate	   27	   4	  
Danazol	   80	   40	  
Droloxifene	  citrate	   16	   34	  
Endoxifen	   251	   27	  
4-­‐OH	  Tamoxifen	   139	   34	  
Tamoxifen	  citrate	   37	   11	  
Toremifene	   56	   7	  
	  
In	   a	   different	   investigation	   [27],	   the	   plasma	   and	   breast	   tumour	   levels	   of	   4-­‐OH	   tamoxifen	   were	  
determined	   after	   (i)	   oral	   dosing	   (20	   mg/day),	   and	   (ii)	   topical	   application	   of	   a	   gel	   (2	   mg/day),	   both	  
formulations	   containing	   the	   metabolite,	   not	   tamoxifen.	   	   The	  median	   plasma	   concentration	   following	  
oral	  administration	  was	  1.50	  ng.mL-­‐1,	  approximately	  an	  order	  of	  magnitude	  greater	  than	  that	  detected	  
post-­‐application	  to	  the	  skin	  (0.16	  ng.mL-­‐1).	  	  In	  contrast,	  the	  respective	  levels	  in	  breast	  tumour	  differed	  by	  
only	   2-­‐3	   fold:	   oral,	   4.2	   ng.g-­‐1,	  versus	   topical,	   1.7	   ng.g-­‐1.	   	   It	  was	   pointed	   out	   that	   these	   concentrations	  
would	  both	  be	  effectively	  anti-­‐estrogenic	  and	  that	  topical	  administration,	  relative	  to	  oral	  dosing,	  had	  the	  
obvious	  advantage	  of	  delivering	  a	  useful	  quantity	  of	  drug	  to	  the	  target	  tissue	  while	  minimising	  systemic	  
exposure.	  
It	  is	  also	  worth	  noting	  that	  endoxifen,	  another	  metabolite	  of	  tamoxifen,	  is	  similar,	  in	  terms	  of	  estrogen	  
binding	  and	  estradiol-­‐induced	  proliferation	  activities,	   to	  4-­‐OH	  tamoxifen	   [9,10,14].	   	  After	  a	  20	  mg	  oral	  
dose	  of	  tamoxifen,	  in	  fact,	  endoxifen	  plasma	  levels	  have	  been	  reported	  to	  be	  as	  high	  as	  6	  times	  those	  of	  
the	  4-­‐OH	  metabolite	  [9].	  	  Given	  that	  the	  percutaneous	  delivery	  of	  endoxifen	  has	  been	  established	  in	  this	  
study	  and	  previously,	  and	  taking	  into	  account	  its	  relative	  pharmacological	  potency,	  it	  is	  again	  reasonable	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to	   hypothesise	   that	   the	   topical	   application	   of	   this	   compound	   directly	   to	   the	   breast	   may	   permit	  
attainment	  of	  sufficient	  local	  tissue	  concentrations	  to	  produce	  a	  useful	  anti-­‐cancer	  outcome.	  
	  
4.	  Conclusions	  
The	  maximum	  skin	  fluxes	  of	  a	  series	  of	  highly	   lipophilic	  compounds	  with	  known	  activity	  against	  breast	  
cancer	   have	   been	   predicted	   theoretically	   and	   measured	   experimentally	   in	   a	   well-­‐accepted	   model	  
system.	  	  Agreement	  between	  prediction	  and	  measurement	  was	  good.	  	  The	  calculated	  rates	  of	  uptake	  of	  
the	   drugs,	   when	   applied	   to	   the	   entire	   breast	   surface	   from	   an	   optimised	   formulation,	   suggest	   that	  
effective,	  local	  tissue	  and	  tumour	  levels	  should	  be	  achievable,	  with	  the	  additional	  benefit	  that	  systemic	  
adverse	   effects	  may	   be	   substantially	   reduced	   or	   avoided	   completely.	   	   Such	   an	   “outside-­‐in”	   approach	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7.	  Figure	  legends	  
Figure	  1.	   Solubility	  of	  the	  compounds	  studied	  in	  different	  mixtures	  of	  ethanol	  (the	  %v/v	  of	  which	  is	  
indicated	  on	  the	  graph)	  and	  water.	  Each	  value	  shown	  represents	  the	  mean	  of	  3	  replicates	  
(standard	  deviations	  are	  too	  small	  to	  be	  visible	  on	  the	  y-­‐axis	  scale	  employed). 
Figure	  2.	   Ratios	  of	  experimental	  to	  theoretical	  fluxes	  of	  the	  compounds	  studied.	  
 
	  
